HIGHLIGHTS
- who: Stefanie Kochinger and colleagues from the Currently, there is no universal vaccine available that would protect against all , known serotypes of BTVThe VRP technology is not restricted to , antigens but may be used to express , antigen of other BTV serotypes as well. Thus, in case a new serotype emerges in a non-endemic region, a recombinant VRP vaccine matching this serotype could be rapidly produced and used for emergency vaccination. This should be particularly valuable for BTV strains for which inactivated vaccines are not readily available because the corresponding viruses do not propagate well in cell . . .

If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.